Drug Trial Radar · NCT07932132
Immunogenicity and Safety of Freeze-Dried Human Rabies Vaccine (Vero Cell) in Patients Infected With Human Immunodeficiency Virus (HIV)
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Aug 8, 2026
Primary completion
Jun 30, 2027
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- Liaoning Chengda Biotechnology CO., LTDIndustry
- Sponsor type
- Industry
- Collaborators
- Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control
- First posted
- Nov 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, open-label, randomized controlled clinical trial designed to evaluate rabies virus neutralizing antibody responses to rabies vaccination among patients infected with human immunodeficiency virus (HIV). Eligible participants will be divided into two groups according to baseline CD4+ T cell count before randomization. Within each group, participants will be randomly assigned to one of two different rabies vaccination regimens for simulated post-exposure prophylaxis. Blood samples will be collected before vaccination and at scheduled time points after vaccination. Rabies virus neutralizing antibody titers will be tested to assess the seroconversion rate and geometric mean concentration (GMC). Adverse events after vaccination will also be recorded.
Conditions
- Rabies
- HIV Infections
Interventions
Rabies Vaccine (Vero Cell) for Human Use, Freeze-driedBiological
0.5mL for each dose, manufactured by Liaoning Chengda Biotechnology CO., LTD, administered by intramuscular injection into the deltoid muscle of the lateral upper arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Seroconversion rate and geometric mean concentration (GMC) of rabies virus neutralizing antibodies at 14 days after completion of the full vaccination courseTime frame: 14 days after completion of the full vaccination course
- Incidence of adverse events after vaccinationTime frame: 30 minutes, 0-7 days, and 8-14 days after each vaccine dose
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The Fourth People's Hospital of Nanning City
Nanning, Guangxi, China · Recruiting
Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention
Nanning, Guangxi, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.